Impel Pharmaceuticals Inc., along with its affiliate, filed first amended joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on February 25, 2024. As per the plan filed, Other Priority Claims of $0.15 million shall be paid in full in cash. Prepetition Term Loan Claims of $127.03 million shall receive in full its pro rata share in cash from Distributable Cash and Contingent Sale Proceeds.

General Unsecured Claims of $4.3 million shall be recovered 2.3% i.e., $0.10 million of its pro rata share in cash. There are no changes in treatment of any other claim class and sources of plan funding. Impel Pharmaceuticals Inc., along with its affiliate, filed solicitation version of first amended joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on February 26, 2024.

As per the plan filed, there are no changes in treatment of any claim class and sources of plan funding. Impel Pharmaceuticals Inc., along with its affiliate, filed a revised first amended joint plan of liquidation in the US Bankruptcy Court on March 27, 2024. As per the plan filed, there are no changes in treatment of any claim class or sources of plan funding.

Impel Pharmaceuticals Inc., along with its affiliate, filed its second revised first amended joint plan of liquidation in the US Bankruptcy Court on April 1, 2024. As per the plan filed, there are no changes in treatment of any claim class or sources of plan funding.